Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:02 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,126 matching trials from the live ClinicalTrials.gov search.
Filters: San Francisco, California Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sham Surgery
Biological · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Nov 3, 2026, 7:02 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Hypertension Remote Monitoring Evaluation Redesign

NCT06113458
View directory record Official record
Conditions
Hypertension
Interventions
Standard and One-time Training, Standard and Practice Facilitation, High-intensity and One-time Training, High-intensity and Practice Facilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 7:02 PM EST
Terminated Not applicable Interventional Results available

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT05273385
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Interventions
Nanodropper
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 3, 2026, 7:02 PM EST
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer

NCT00034333
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
MTC-DOX for Injection
Drug
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Long Beach, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 1 Interventional Results available

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

NCT00603447
View directory record Official record
Conditions
Relapsed Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 3 Interventional Results available

Use of NPSP558 in the Treatment of Hypoparathyroidism

NCT00732615
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Placebo, NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Scottsdale, Arizona • Lakewood, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Nov 3, 2026, 7:02 PM EST
Completed Not applicable Interventional Results available

Treating People With Post-Traumatic Stress Disorder With Cognitive Behavioral Therapy for Insomnia

NCT00881647
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive Behavioral Treatment for Insomnia (CBT-I)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Nov 3, 2026, 7:02 PM EST
Terminated Phase 4 Interventional Results available

Impact of Topical Tranexamic Acid in Breast Reconstruction

NCT05807074
View directory record Official record
Conditions
Breast Cancer
Interventions
Tranexamic Acid, Saline
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Nov 3, 2026, 7:02 PM EST
Active, not recruiting Phase 2 Interventional

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT03708224
View directory record Official record
Conditions
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Atezolizumab, Tocilizumab, Tiragolumab
Biological
Lead sponsor
Alain Algazi
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 3 Interventional Results available

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325442
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) sustained release tablets, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Nov 3, 2026, 7:02 PM EST
Completed No phase listed Observational

The Second Multicenter Hemophilia Cohort Study

NCT00341705
View directory record Official record
Conditions
Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
2,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
39
States / cities
Tucson, Arizona • Davis, California • Orange, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 3, 2026, 7:02 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162
View directory record Official record
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 7:02 PM EST
Completed Not applicable Interventional Results available

Comparison of Three Methods of Hemoglobin Monitoring

NCT01284296
View directory record Official record
Conditions
Digital Block
Interventions
Lidocaine digital block, Masimo SpHb continuous hemoglobin monitor
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Nov 3, 2026, 7:02 PM EST
Completed No phase listed Observational Accepts healthy volunteers

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

NCT00259727
View directory record Official record
Conditions
Diabetes, HIV Infections, Insulin Resistance
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 72 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Nov 3, 2026, 7:02 PM EST
Not listed Phase 2 Interventional

Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients

NCT00081783
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Xcellerated T Cells
Drug
Lead sponsor
Xcyte Therapies
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Greenbrae, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 7:02 PM EST
Completed Not applicable Interventional Results available

National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

NCT03982459
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Decision support tool
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Nov 3, 2026, 7:02 PM EST
Approved For Marketing No phase listed Expanded access

Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study

NCT02577562
View directory record Official record
Conditions
Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms, Juxtarenal Aneurysms
Interventions
Zenith® Fenestrated AAA Endovascular Graft
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
San Francisco, California • Gainesville, Florida • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Nov 3, 2026, 7:02 PM EST
Completed Not applicable Interventional

Better Effectiveness After Transition - Heart Failure

NCT01360203
View directory record Official record
Conditions
Heart Failure
Interventions
Structured Telephone / Remote Outpatient Monitoring
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
1,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Davis, California • Irvine, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 2 Interventional Results available

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

NCT01030861
View directory record Official record
Conditions
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions
Teplizumab, Placebo infusion
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 4 Interventional Results available

Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

NCT04087096
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bone Loss
Interventions
Denosumab, Placebo, Zoledronic Acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

NCT01940341
View directory record Official record
Conditions
HBeAg-negative Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Nov 3, 2026, 7:02 PM EST
Completed Phase 2 Interventional Results available

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 7:02 PM EST
Completed Not applicable Interventional

Effects of High-intensity Exercise Training on Physical Fitness, Cognition, Language in Post-stroke Aphasia

NCT06185023
View directory record Official record
Conditions
Aphasia, Acquired, Aphasia, Aphasia, Fluent, Aphasia Non Fluent
Interventions
Low-intensity physical exercise, High-intensity physical exercise
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Berkeley, California • Hayward, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 3, 2026, 7:02 PM EST
Completed No phase listed Observational

Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury

NCT00605527
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Days to 18 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
Fresno, California • Los Angeles, California • Oakland, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Nov 3, 2026, 7:02 PM EST